US2017022255A1PendingUtilityA1
Bluetongue virus recombinant vaccines and uses thereof
Est. expiryMar 12, 2030(~3.6 yrs left)· nominal 20-yr term from priority
A61K 39/12A61P 37/04A61P 31/20A61P 31/12C12N 15/8258A61K 39/15C12N 2720/12134A61K 2039/5252A61K 2039/55566A61K 2039/517A61K 2039/55505C07K 14/005A61K 2039/55561A61K 2039/55577A61K 2039/552
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV.
Claims
exact text as granted — not AI-modified1 - 25 . (canceled)
26 . A method of producing a BTV antigen comprising: (a) culturing within a duckweed culture medium a duckweed plant or duckweed nodule, wherein the duckweed plant or the duckweed nodule is stably transformed with a plasmid to express the antigen, and wherein the antigen is expressed from a nucleotide sequence comprising a coding sequence for the antigen; and (b) collecting the antigen from the duckweed plant or duckweed nodule.
27 . The method of claim 26 , wherein the BTV antigen is selected from the group consisting of BTV VP2, BTV VP5, or a combination thereof.
28 . The method of claim 27 , wherein the BTV antigen has at least 80% sequence identity to a polypeptide having a sequence as set forth in SEQ ID NO:4, 6, or 10.
29 . The method of claim 27 , wherein the BTV antigen is BTV VP2 having at least 80% sequence identity to SEQ ID NO:4 or 6.
30 . The method of claim 27 , wherein the BTV antigen is BTV VP5 having at least 80% sequence identity to SEQ ID NO:10.
31 . The method of claim 26 , wherein the nucleotide sequence comprises a sequence having at least 70% sequence identity to the sequence as set forth in SEQ ID NO: 1, 2, 3, 5, 7, 8, or 9.
32 . The method of claim 27 , wherein the plasmid comprises an alpha amylase leader sequence, an RbcS leader sequence, or a combination thereof.
33 . The method of claim 32 , wherein the alpha amylase leader sequence comprises a sequence as set forth in SEQ ID NO:26.
34 . The method of claim 32 , wherein the RbcS leader sequence comprises a sequence as set forth in SEQ ID NO:27.Join the waitlist — get patent alerts
Track US2017022255A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.